Key result
Astragalin demonstrated procoagulant effects in vitro and in a heparin-induced rat model by shortening coagulation time and increasing platelet count.
Why the study?
Astragalin has anti-inflammatory and other bioactive properties, but studies on its potential procoagulant effect had not been reported.
Does astragalin demonstrate procoagulant activity in vitro and in a heparin-induced rat model?
Does astragalin demonstrate procoagulant activity in vitro and in a heparin-induced rat model?
Astragalin demonstrates procoagulant effects by promoting both intrinsic and extrinsic coagulation systems in preclinical models.
Astragalin's procoagulant activity in rat models should not yet alter clinical anticoagulation; leaves open potential for heparin reversal agents.
Astragalin, isolated from flowers of Rosa chinensis Jacq., is a kind of flavonoid, with anti-inflammatory, antioxidant, antiviral, analgesic, antibacterial, antiallergic, and antihepatotoxic effects. However, no studieson the procoagulant effect of astragalin have been reported. This study aimed to investigate the procoagulant activity of astragalin and its mechanism. Its procoagulant effect was investigated by activated partial thromboplastin time (APTT), thrombin time (TT), prothrombin time (PT), and fibrinogen (FIB) in vitro, and a rat model established by heparin sodium was used to evaluate the mechanism for the procoagulant effect in vivo. The results showed that astragalin had good procoagulant effects compared with the control group in vitro. Compared with the model group in vivo, astragalin could shorten the coagulation time and significantly increase the number of platelets. Meanwhile, astragalin could significantly reduce the effectual time of PT and APTT and increase the content of FIB. The contents of 6-keto-PGF1α and eNOS significantly decreased. Astragalin could increase whole blood viscosity (WBV), plasma viscosity (PV), erythrocyte sedimentation rate (ESR) and packedcell volume (PCV). All of the above revealed that astragalin had good procoagulant effects by promoting the intrinsic and extrinsic coagulation system.
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) studied Heparin-induced anticoagulation. Astragalin vs. Control/model group was evaluated on Procoagulant activity (APTT, TT, PT, FIB). Astragalin demonstrated procoagulant effects in vitro and in a heparin-induced rat model by shortening coagulation time and increasing platelet count.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: